Plant Name: Cullen corylifolium
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| FFAR1; FFAR4; | |
| PTPN1; | |
| CES1; FAAH; TDP1; BLM; TERT; HPGD; HSD17B1; HSD17B10; ALOX15; TNKS; CES2; AOX1; | |
| ACHE; MGAM; | |
| ABL1; MAPK1; EGFR; | |
| CA2; CA12; CA1; CA9; CA14; CA7; CA4; ODC1; | |
| PPARA; PPARD; PPARG; | |
| ESR1; ESR2; | |
| ESRRB; ESRRA; | |
| MAOA; ALDH2; | |
| HIF1A; TP53; NFKB1; | |
| ABCG2; | |
| SLCO1B3; SLCO1B1; | |
| LMNA; RAB9A; NPC1; FABP3; FABP5; MAPT; THPO; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 2 | CYP2A13 | Cytochrome P450 2A13 | Q16696 | CHEMBL3542436 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
| Enzyme_unclassified | CES1 | Acyl coenzyme A:cholesterol acyltransferase | P23141 | CHEMBL2265 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | CES2 | Carboxylesterase 2 | O00748 | CHEMBL3180 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | ODC1 | Ornithine decarboxylase | P11926 | CHEMBL1869 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.590E-12 | 2.885E-09 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 7.187E-11 | 9.206E-08 | ALOX15, AOX1, CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, TBXAS1 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.679E-11 | 9.289E-08 | CA1, CA12, CA14, CA2, CA4, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.068E-10 | 2.047E-07 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 2.848E-10 | 2.696E-07 | CES1, CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, ESR1, HSD17B1, NPC1, PPARD |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.257E-10 | 2.955E-07 | BLM, CA1, CA12, CA2, CA4, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB, PPARA, PPARD, PPARG, PTPN1, TNKS, TP53 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 9.674E-10 | 7.022E-07 | CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.394E-09 | 9.794E-07 | CA1, CA12, CA2, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 2.606E-09 | 1.621E-06 | CES1, CES2, CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.200E-09 | 2.980E-06 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.704E-09 | 3.105E-06 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 6.542E-09 | 3.474E-06 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, TBXAS1 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 9.714E-09 | 4.919E-06 | CYP3A4, ESR1, ESR2, ESRRA, ESRRB, HSD17B1, NPC1 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 4.371E-08 | 1.741E-05 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.196E-07 | 4.056E-05 | CYP1A2, CYP2C9, CYP3A4 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.211E-07 | 4.056E-05 | CA2, CA4, CA9, EGFR, HPGD, SLCO1B1, SLCO1B3, TSHR |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 1.714E-07 | 5.490E-05 | ESR1, ESR2, ESRRA, ESRRB, PPARA, PPARD, PPARG |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 2.077E-07 | 6.370E-05 | CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0065007; biological regulation | GO:0010817; regulation of hormone levels | 4.854E-07 | 1.409E-04 | ACHE, CYP3A4, EGFR, ESR1, FFAR1, FFAR4, HIF1A, HSD17B1, NFKB1, PPARD, SLCO1B1 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 5.360E-07 | 1.536E-04 | ABL1, CA2, CA7, EGFR, HIF1A, MAPK1, NPC1, TNKS |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 7.031E-07 | 1.938E-04 | ESR1, ESR2, ESRRA, ESRRB, PPARA, PPARD, PPARG |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.619E-07 | 2.074E-04 | CYP1A2, CYP2A13, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 1.039E-06 | 2.632E-04 | CYP2A13, CYP2A6, CYP2D6 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 1.284E-06 | 3.176E-04 | ESR1, ESR2, ESRRA, ESRRB, PPARA, PPARD, PPARG |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.664E-06 | 4.026E-04 | ABCG2, ACHE, AOX1, BLM, EGFR, ESR1, ESR2, HPGD, MAPK1, MAPT, NFKB1, ODC1, PPARG, RAB9A, SMN1, SMN2, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.540E-06 | 7.411E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 4.410E-06 | 8.891E-04 | ALOX15, EGFR, PPARA, PPARD, TP53 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 9.810E-06 | 1.780E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 9.810E-06 | 1.780E-03 | CYP2A13, CYP2A6 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.397E-05 | 2.453E-03 | ABL1, BLM, EGFR, ESR1, MAPK1, NFKB1, NPC1, PPARG |
| BP | GO:0050896; response to stimulus | GO:0070920; regulation of production of small RNA involved in gene silencing by RNA | 1.630E-05 | 2.772E-03 | EGFR, ESR1, TERT |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.923E-05 | 3.221E-03 | HIF1A, LMNA, PPARD, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 2.937E-05 | 4.411E-03 | CYP2D6, CYP3A4 |
| BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 2.937E-05 | 4.411E-03 | ABL1, HIF1A |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.937E-05 | 4.411E-03 | CA2, CA7 |
| MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 2.918E-05 | 4.411E-03 | ABCG2, ACHE, AOX1, BLM, EGFR, HIF1A, HPGD, MAPT, NFKB1, ODC1, PPARD, PPARG, TERT, TP53 |
| MF | GO:0003824; catalytic activity | GO:0047374; methylumbelliferyl-acetate deacetylase activity | 2.937E-05 | 4.411E-03 | CES1, CES2 |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 3.035E-05 | 4.504E-03 | ABCG2, ABL1, CA12, CA2, CA7, EGFR, ESR1, HIF1A, MAPK1, TP53 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 3.125E-05 | 4.598E-03 | FFAR4, NFKB1, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 3.254E-05 | 4.685E-03 | ABL1, BLM, EGFR, MAPK1, NFKB1, PPARG, TP53, TSHR |
| BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 3.288E-05 | 4.685E-03 | EGFR, ESRRB, HIF1A |
| MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 3.288E-05 | 4.685E-03 | ESR1, PPARA, TERT |
| BP | GO:0050896; response to stimulus | GO:0080134; regulation of response to stress | 3.738E-05 | 5.055E-03 | ABL1, EGFR, ESR1, FFAR4, HIF1A, LMNA, MAPK1, MAPT, NFKB1, PPARA, PPARD, PPARG, PTPN1, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 4.422E-05 | 5.697E-03 | HIF1A, TERT, TP53 |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 4.486E-05 | 5.747E-03 | CYP1A2, EGFR, ESR1, ESRRA, HPGD |
| BP | GO:0008152; metabolic process | GO:1901615; organic hydroxy compound metabolic process | 4.538E-05 | 5.778E-03 | ALDH2, ALOX15, CES1, CYP3A4, HIF1A, MAOA, NPC1, PPARD |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 5.862E-05 | 7.052E-03 | ESR1, ESR2 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 5.945E-05 | 7.113E-03 | FABP3, PPARA, PPARD, PPARG |
| BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 6.302E-05 | 7.458E-03 | ESRRB, HIF1A, NFKB1, PPARA |
| BP | GO:0008152; metabolic process | GO:0009299; mRNA transcription | 6.559E-05 | 7.684E-03 | HIF1A, PPARD, TP53 |
| BP | GO:0050896; response to stimulus | GO:0043627; response to estrogen | 8.324E-05 | 9.590E-03 | CA2, ESR1, MAPK1, PPARG |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.384E-14 | 5.024E-11 | CA1, CA12, CA14, CA2, CA4, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.266E-14 | 5.716E-12 | CA12; CA1; CA2; CA4; CA7; CA9; CA14 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.363E-11 | 2.942E-09 | CYP2C9; CYP2A6; MAOA; CYP2D6; CYP1A2; AOX1; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.506E-08 | 1.462E-06 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 9.085E-08 | 3.975E-06 | CYP2C9; CYP2A6; CYP2A13; CYP2D6; CYP1A2; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.830E-07 | 6.403E-06 | CYP2C9; CYP2A6; CYP2A13; CYP1A2; CYP3A4; CYP2C19 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.165E-06 | 3.397E-05 | CYP2C9; CYP2D6; MAOA; ALOX15; MAPK1; CYP2C19 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.304E-06 | 5.782E-05 | MGAM; MAOA; ODC1; ALOX15; CYP2C19; CYP3A4; HSD17B10; CYP2C9; CYP2A6; ALDH2; HSD17B1; TBXAS1; CYP1A2; AOX1; CES1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.603E-06 | 4.007E-05 | CYP2C9; CYP2A6; CYP1A2; AOX1; CYP3A4 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 2.160E-06 | 4.726E-05 | FABP3; FABP5; PPARG; PPARA; PPARD |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.491E-06 | 4.844E-05 | SLCO1B1; CA2; SLCO1B3; CYP3A4; ABCG2 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.638E-05 | 3.551E-04 | ABL1; MAPK1; PPARG; HIF1A; TP53; EGFR; NFKB1; PPARD |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 6.592E-06 | 1.049E-04 | ALDH2; MAOA; CYP1A2; AOX1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.161E-05 | 1.693E-04 | CYP2A6; CYP3A4; CES2; CES1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.827E-05 | 4.784E-04 | CYP2C9; ALOX15; TBXAS1; CYP2C19 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 4.900E-05 | 5.478E-04 | MAPK1; TP53; EGFR; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 5.322E-05 | 5.478E-04 | MAPK1; PPARA; TP53; EGFR; NFKB1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 5.199E-05 | 5.478E-04 | MAPK1; TP53; HIF1A; EGFR |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 6.899E-05 | 6.708E-04 | MAPK1; ESR1; NFKB1; ESR2 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 7.283E-05 | 6.708E-04 | ABL1; MAPK1; TP53; NFKB1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.575E-04 | 1.253E-03 | MAPK1; TP53; EGFR; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.374E-04 | 1.806E-03 | MAPK1; ESR1; EGFR; ESR2 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.846E-04 | 2.589E-03 | MAPK1; TP53; HIF1A; ESR1; EGFR |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.763E-04 | 1.934E-03 | MAPK1; HIF1A; EGFR; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.636E-04 | 2.882E-03 | MAPK1; TP53; ESR1; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 4.940E-04 | 2.882E-03 | ABL1; MAPK1; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 8.810E-04 | 4.405E-03 | LMNA; MAPK1; TP53; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.077E-03 | 4.960E-03 | MAPK1; MAPT; TP53; EGFR; NFKB1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.650E-04 | 1.932E-03 | MAPK1; TP53; EGFR |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.106E-03 | 8.990E-03 | ABL1; MAPK1; TP53; EGFR; NFKB1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 9.322E-05 | 7.769E-04 | MAPK1; PPARG; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 6.670E-04 | 3.648E-03 | MAPK1; TP53; EGFR |
| hsa00280 | Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | 4.234E-04 | 2.745E-03 | ALDH2; AOX1; HSD17B10 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 5.364E-04 | 3.028E-03 | MAPK1; TP53; EGFR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.031E-03 | 4.875E-03 | MAPK1; TP53; EGFR |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 7.025E-04 | 3.725E-03 | MAPK1; NFKB1; PPARD |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.220E-03 | 9.041E-03 | HPGD; PPARG; TP53; NFKB1 |
| hsa00330 | Arginine and proline metabolism_Homo sapiens_hsa00330 | 4.778E-04 | 2.882E-03 | ALDH2; MAOA; ODC1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.331E-03 | 5.974E-03 | MAPK1; TP53; EGFR |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 3.188E-03 | 1.162E-02 | MAPK1; PPARA; NFKB1; TSHR |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 5.087E-03 | 1.717E-02 | ABL1; MAPK1; EGFR; NFKB1 |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.385E-03 | 9.406E-03 | ABL1; MAPK1; EGFR |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.500E-03 | 6.563E-03 | PTPN1; MAPK1; EGFR |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 2.971E-03 | 1.130E-02 | PPARG; TP53; NFKB1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 3.638E-03 | 1.299E-02 | MAPK1; HIF1A; EGFR |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 7.392E-04 | 3.805E-03 | HSD17B1; CYP1A2; CYP3A4 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.031E-03 | 4.875E-03 | ABL1; MAPK1; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 4.505E-03 | 1.577E-02 | PTPN1; PPARA; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 7.652E-03 | 2.480E-02 | MAPK1; PPARG; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 8.303E-03 | 2.642E-02 | RAB9A; TP53; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.007E-02 | 3.092E-02 | MAPK1; TP53; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.886E-03 | 1.943E-02 | MAPK1; TP53; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.468E-02 | 4.281E-02 | MAPK1; MAPT; HSD17B10 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.446E-02 | 4.281E-02 | MAPK1; HIF1A |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.732E-02 | 4.888E-02 | MAPK1; HIF1A |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.539E-02 | 4.414E-02 | MAPK1; TP53 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.311E-02 | 3.957E-02 | MAPK1; NFKB1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 9.814E-03 | 3.067E-02 | MAOA; NFKB1 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 3.058E-03 | 1.139E-02 | MAPK1; EGFR |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 5.103E-03 | 1.717E-02 | MAOA; AOX1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.221E-03 | 9.041E-03 | CA2; CA4 |
| hsa00340 | Histidine metabolism_Homo sapiens_hsa00340 | 2.419E-03 | 9.406E-03 | ALDH2; MAOA |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 9.097E-05 | 7.769E-04 | CYP2A6; CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | African trypanosomiasis | B56 | ODC1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; FAAH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; ESRRA |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; ACHE; FAAH |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; MAPK1; CA9; ABL1; EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | MGAM |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1 |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | CES1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | TBXAS1; ESRRA |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA |
| A00-B99: Certain infectious and parasitic diseases | Burns and burn infection | A00-B99 | ODC1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; MAPK1; CA1; CA9; ABL1; NFKB1; ESR1; ESR1; EGFR; ACHE |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | CES1; PPARD |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; FFAR1; MGAM; PPARG |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Intestinal cancer | NA | ABL1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; ESR1; ESR1; TERT; EGFR; EGFR; EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR |
| C00-D49: Neoplasms | Prostate cancer | C61 | ABL1; ESR1; TERT; EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; MAOA; ACHE; FAAH |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ABL1; ESR1 |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | ABL1; EGFR |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; EGFR |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| C00-D49: Neoplasms | Melanoma | C43 | TERT; EGFR |
| NA: NA | Menopausal disorder | NA | ESR1 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | ABL1; ABL1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; FFAR1; NFKB1; PPARD; TBXAS1; MGAM; PPARG; PPARG |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TBXAS1; PPARG |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | FAAH |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; ALDH2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; TERT; EGFR; EGFR; EGFR; ODC1 |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ALDH2 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; TERT; EGFR; EGFR |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; TERT |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; EGFR; EGFR |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | TBXAS1 |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; PPARD; PPARD; PPARG |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; EGFR |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | CES1; PPARD; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | MGAM |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperglycemia | R73.9 | MGAM |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | CES1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| I00-I99: Diseases of the circulatory system | Peripheral vascular disease | I73.9 | CES1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; ACHE |
| C00-D49: Neoplasms | Glioma | C71 | ABL1; EGFR; EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT; EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; ACHE; ACHE; ACHE; MAPT; PPARG; PPARG |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | MGAM |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | ABL1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | ABL1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; ESRRA |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle disease | M60-M63 | MGAM |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; EGFR; EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2 |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | ABL1; CES1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Dengue fever | A90 | MGAM |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PPARG |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |